Not currently enrolling

Dose-escalation and expansion study of BAY 3375968 (anti-CCR8 antibody) as monotherapy and in combination with pembrolizumab in selected advanced solid tumors

This study will evaluate BAY 3375968 as a new immunotherapeutic agent in advanced solid tumor settings of high medical need.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is not currently enrolling.

United States (Nationwide)

Additional Study Information

Principal Investigator

Shetal Patel
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Bladder, Breast, Colorectal, Head and Neck, Kidney, Lung, Melanoma, Other Cancers)

IRB Number

24-1885

ClinicalTrials.gov

NCT05537740

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.